COULTREON BIOPHARMA
Board
7 directors, 1 auditor, no change since October 2026Deed of 02-10-2026Appointment: BDO BEDRIJFSREVISOREN BV (statutory auditor)Permanent representative: Ellen LOMBAERTS · General meeting of 27-09-2026
Director, permanent representative Pierre Raboisson
appointed by deed of 05-05-2026
2-year term from 2026
SKJ Consult BV
Director and cFO, permanent representative Guy Peeters
appointed by deed of 02-03-2026
term without a fixed end
earlier director, until 05-05-2026
also on the board of 1 other company
Statutory auditor, permanent representative Ellen LOMBAERTS
appointed by deed of 02-10-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Two directors jointlydeed of 05-05-2026
Permanent representatives 2
Mandates through the years
10 names, the dashed line is todayPierre Raboisson BV
Director
Director
Lawrence Blatt
Director
Director
SKJ Consult
Director and cFO
Director and cFO
Lawrence M BLATT
Director
Director
Maha Katabi
Director
Director
Max Klement
Director
Director
Rogier Rooswinkel
Director
Director
BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
Statutory auditor
Statutory auditor
Vuldex Consulting BV
Bestuurder en chief legal officer
Bestuurder en chief legal officer
Pierre RABOISSON
Director (not named in the articles)
Director (not named in the articles)
BoardOther functionEarlierRest of the termmandate already running before its first mentionend not dated
Mandates as a list
- Pierre Raboisson BV
- Director, appointed by deed of 17-06-2025, still in office
- Managing director and cEO, appointed by deed of 01-12-2025, ended, last mentioned on 01-12-2025
- Lawrence Blatt
- Director, appointed by deed of 02-03-2026, still in office
- SKJ Consult
- Director and cFO, appointed by deed of 02-03-2026, until 05-05-2026
- Director and cFO, appointed by deed of 02-03-2026, still in office
- Director and cFO, appointed by deed of 02-03-2026, still in office
- Lawrence M BLATT
- Director, since before 05-05-2026
- Maha Katabi
- Director, appointed by deed of 05-05-2026, still in office
- Max Klement
- Director, appointed by deed of 05-05-2026, still in office
- Rogier Rooswinkel
- Director, appointed by deed of 05-05-2026, still in office
- BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
- Statutory auditor, appointed by deed of 02-10-2026, still in office
- Vuldex Consulting BV
- Bestuurder en chief legal officer, appointed by deed of 01-12-2025, until 12-12-2025
- Bestuurder en chief legal officer, appointed by deed of 01-12-2025, ended, last mentioned on 01-12-2025
- Pierre RABOISSON
- Director (not named in the articles), appointed by deed of 03-02-2025, until 01-04-2025
Control
This company
COULTREON BIOPHARMA
Capital
- Contribution
- €21,663,222.22
- Shares
- 72,414,549 in the deed of 03-02-2025 and 2 later capital increases
- Contribution per share
- €0.30
- Source
- deed of 05-05-2026
Articles of association
deed of 05-05-2026 (in Dutch)- Name, seat, purpose and duration
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board and representation
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 1 directorAt most 7 directors1 director3 directors“De uitgifte van Effecten aan partijen die de vennootschap voorzien van apparatuur leases, onroerend goed leases, leningen of kredietlijnen…”“Het besluit om een vennootschap over te nemen, een fusie of consolidatie met of in een vennootschap voor te stellen, alle of vrijwel alle…”“Tenzij het bestuursorgaan hiervoor toestemming heeft gegeven via een Business Plan, schulden aangaan (met uitzondering van schulden die in…”“Tenzij het bestuursorgaan hiervoor toestemming heeft gegeven via een Business Plan, mag er geen enkele uitgave uit eigen middelen worden…”
- Capital, shares and profit
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Alleen samen met de Klasse A Aandelen waarop de betreffende Investeerder heeft ingeschreven in het kader van de Kapitaalverhoging A (zoals…”
- Financial instrumentThe company can also issue securities other than shares, such as bonds or warrants.
- “Anti-dilutie inschrijvingsrecht, EUR”“10 jaar, 23:59”
- General meeting and financial year
- Financial yearThe company draws up its annual accounts over this twelve-month period.
- From 1 January to 31 December
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Second Wednesday of June at 17:00
- Audit, dissolution and liquidation
- Auditor ruleThe articles set how a statutory auditor is appointed and what they check.
- “3 jaar, commissarissen”
Shareholders
After 2 capital increases
deed of 05-05-2026 ↗
- GALAPAGOS NV (BE 0466.460.429) 23,360,039 shares · €21,663,222.22 in kind
At incorporation
deed of 03-02-2025 ↗
- Pierre Raboisson 170 shares (21.8%) · €17,000
- Pieter Peeters 150 shares (19.2%) · €15,000
- Francois Gonzalvez 150 shares (19.2%) · €15,000
- Marie De Vulder 150 shares (19.2%) · €15,000
- Joost Kolkman 80 shares (10.3%) · €8,000
- Sandrine Vendeville 80 shares (10.3%) · €8,000
Capital transactions
Capital over time
- 05-05-2026 Capital increase · to €21,663,222.22 · 23,360,039 new shares · in kind
- 05-05-2026 Capital increase · to €53,293,336.74 · 49,053,730 new shares · inschrijving
- 03-02-2025 Incorporation · €78,000 · 780 shares